183 related articles for article (PubMed ID: 30385871)
21. Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol.
Seidah NG
Nat Struct Mol Biol; 2017 Oct; 24(10):785-786. PubMed ID: 28981076
[No Abstract] [Full Text] [Related]
22. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
[TBL] [Abstract][Full Text] [Related]
23. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
24. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
25. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
[TBL] [Abstract][Full Text] [Related]
26. The Cholesterol-Modulating Effect of Methanol Extract of Pigeon Pea (
Chang HY; Wu JR; Gao WY; Lin HR; Chen PY; Chen CI; Wu MJ; Yen JH
Molecules; 2019 Jan; 24(3):. PubMed ID: 30704067
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels.
Goedeke L; Rotllan N; Canfrán-Duque A; Aranda JF; Ramírez CM; Araldi E; Lin CS; Anderson NN; Wagschal A; de Cabo R; Horton JD; Lasunción MA; Näär AM; Suárez Y; Fernández-Hernando C
Nat Med; 2015 Nov; 21(11):1280-9. PubMed ID: 26437365
[TBL] [Abstract][Full Text] [Related]
28. microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator.
Jiang H; Zhang J; Du Y; Jia X; Yang F; Si S; Wang L; Hong B
Atherosclerosis; 2015 Dec; 243(2):523-32. PubMed ID: 26523989
[TBL] [Abstract][Full Text] [Related]
29. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
30. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
32. Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network.
Chae HS; You BH; Kim DY; Lee H; Ko HW; Ko HJ; Choi YH; Choi SS; Chin YW
Sci Rep; 2018 Apr; 8(1):6737. PubMed ID: 29712938
[TBL] [Abstract][Full Text] [Related]
33. PCSK9: an emerging target for treatment of hypercholesterolemia.
Duff CJ; Hooper NM
Expert Opin Ther Targets; 2011 Feb; 15(2):157-68. PubMed ID: 21204732
[TBL] [Abstract][Full Text] [Related]
34. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia.
Sultan Alvi S; Ansari IA; Khan I; Iqbal J; Khan MS
Free Radic Biol Med; 2017 Jul; 108():394-403. PubMed ID: 28412198
[TBL] [Abstract][Full Text] [Related]
35. Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells.
Choi HK; Hwang JT; Nam TG; Kim SH; Min DK; Park SW; Chung MY
Food Funct; 2017 Dec; 8(12):4582-4591. PubMed ID: 29130084
[TBL] [Abstract][Full Text] [Related]
36. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
[TBL] [Abstract][Full Text] [Related]
37. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.
Abidi P; Zhou Y; Jiang JD; Liu J
Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2170-6. PubMed ID: 16100034
[TBL] [Abstract][Full Text] [Related]
38. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
39. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
Dong B; Wu M; Cao A; Li H; Liu J
Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
[TBL] [Abstract][Full Text] [Related]
40. Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia.
O'Hare EA; Wang X; Montasser ME; Chang YP; Mitchell BD; Zaghloul NA
J Lipid Res; 2014 Nov; 55(11):2242-53. PubMed ID: 25201834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
